GeneDx Holdings (WGS) Research & Development (2020 - 2026)

GeneDx Holdings (WGS) has reported Research & Development for 7 consecutive years, with $19.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 57.46% year-over-year to $19.8 million; the TTM figure through Mar 2026 stood at $79.3 million (up 52.14% YoY), while the FY2025 annual figure was $72.0 million, up 57.53% from the prior year.
• Research & Development retreated to $19.8 million in Q1 2026 per WGS's latest filing, from $24.5 million in the prior quarter.
• Across five years, Research & Development topped out at $34.4 million in Q3 2022 and bottomed at $10.9 million in Q2 2024.
• Historically, Research & Development has averaged $19.1 million across 5 years, with a median of $17.0 million in 2024.
• Annual changes were most pronounced in 2023 — Research & Development plunged 58.44% — and 2025, when it surged 111.78%.
• GeneDx Holdings' Research & Development stood at $29.2 million in 2022, then tumbled by 46.78% to $15.6 million in 2023, then fell by 25.52% to $11.6 million in 2024, then soared by 111.78% to $24.5 million in 2025, then fell by 19.3% to $19.8 million in 2026.
• Business Quant data shows WGS's Research & Development at $19.8 million in Q1 2026, $24.5 million in Q4 2025, and $19.8 million in Q3 2025.